pCMV HA hRB-wt Citations (7)

Originally described in: Cyclin D activates the Rb tumor suppressor by mono-phosphorylation.
Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF Elife. 2014 May 29:e02872. doi: 10.7554/eLife.02872. PubMed Journal

---

Articles Citing pCMV HA hRB-wt

Articles
HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation. Bollaert E, Johanns M, Herinckx G, de Rocca Serra A, Vandewalle VA, Havelange V, Rider MH, Vertommen D, Demoulin JB. Cell Signal. 2018 Apr;44:158-170. doi: 10.1016/j.cellsig.2018.01.014. Epub 2018 Feb 16. PubMed
p38gamma is essential for cell cycle progression and liver tumorigenesis. Tomas-Loba A, Manieri E, Gonzalez-Teran B, Mora A, Leiva-Vega L, Santamans AM, Romero-Becerra R, Rodriguez E, Pintor-Chocano A, Feixas F, Lopez JA, Caballero B, Trakala M, Blanco O, Torres JL, Hernandez-Cosido L, Montalvo-Romeral V, Matesanz N, Roche-Molina M, Bernal JA, Mischo H, Leon M, Caballero A, Miranda-Saavedra D, Ruiz-Cabello J, Nevzorova YA, Cubero FJ, Bravo J, Vazquez J, Malumbres M, Marcos M, Osuna S, Sabio G. Nature. 2019 Apr;568(7753):557-560. doi: 10.1038/s41586-019-1112-8. Epub 2019 Apr 10. PubMed
G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. Lee Y, Lahens NF, Zhang S, Bedont J, Field JM, Sehgal A. PLoS Biol. 2019 Apr 30;17(4):e3000228. doi: 10.1371/journal.pbio.3000228. eCollection 2019 Apr. PubMed
Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. Kuganesan N, Dlamini S, Tillekeratne LMV, Taylor WR. J Biol Chem. 2021 Dec;297(6):101365. doi: 10.1016/j.jbc.2021.101365. Epub 2021 Oct 30. PubMed
Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor. Yang W, Jiang XX, Zhao XY, Mao PA. Kaohsiung J Med Sci. 2022 Mar;38(3):244-252. doi: 10.1002/kjm2.12469. Epub 2021 Nov 6. PubMed
Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. Koch J, Schober SJ, Hindupur SV, Schoning C, Klein FG, Mantwill K, Ehrenfeld M, Schillinger U, Hohnecker T, Qi P, Steiger K, Aichler M, Gschwend JE, Nawroth R, Holm PS. Nat Commun. 2022 Aug 10;13(1):4689. doi: 10.1038/s41467-022-32087-5. PubMed
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. De Rosa P, Severi F, Zadran SK, Russo M, Aloisi S, Rigamonti A, Capranico G, Milazzo G, Perini G. Int J Mol Sci. 2023 Mar 12;24(6):5408. doi: 10.3390/ijms24065408. PubMed

If you have published an article using this material, please email us at to have your article added to this page.